CGM capabilities will be integral to artificial pancreas system for automated insulin delivery.

Diabetes research organization JDRF and Becton, Dickinson and Company (BD) have extended their existing type 1 diabetes collaboration to include further development of the latter’s next-generation continuous glucose-sensing platform. The technology is relevant to JDRF’s partnership with the Helmsley Charitable Trust (HCT), which aims to develop artificial pancreas systems that comprise continuous glucose measurement sensors to enable automatic delivery of the right amount of insulin.

“Combined with our existing JDRF collaboration to develop microneedle insulin infusion, this latest collaboration with JDRF and The Helmsley Charitable Trust demonstrates the parties’ commitment to further improving the patient experience and enabling the artificial pancreas,” states Linda Tharby, president for diabetes care at BD Medical.

Back in 2010 BD and JDRF established a collaboration focused on the development of products that deliver insulin from a pump to a patient in either an infusion set or patch-pump configuration. The research program was one of the first nonexclusive industry initiatives undertaken by JDRF as part of its Artificial Pancreas Project, which ultimately aims to speed the development of fully automated diabetes management systems.

Previous articleAbbott Expects Spinoff AbbVie to Be a $17.4B Proprietary Drug-CMO Powerhouse
Next articleSorrento Wins $600K to Develop MRSA Antibodies that Disrupt Quorum Sensing